Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial

Inclusion Criteria: * Stated willingness to comply with all study procedures and availability for the duration of the study period * History of juvenile idiopathic arthritis (JIA) or chronic anterior uveitis (CAU), diagnosed prior to 16 years of age (patient may be older than 16 at time of enrollment) * ≥2 years of age (per FDA approval for use in children with polyarticular JIA) * Weight must be ≥15kg * Formal diagnosis of JIA-associated uveitis or CAU with no other suspected etiology * ≥24 consecutive months of controlled ocular inflammation (≤0.5+ anterior chamber cell, ≤0.5+ vitreous haze, and no active retinal/choroidal lesions in either eye) * ≥24 consecutive months of controlled arthritis verified by a pediatric rheumatologist if defined as JIA-associated uveitis * ≥24 consecutive months of treatment with adalimumab or biosimilar of adalimumab * ≥180 days on a stable dose of adalimumab or biosimilar of adalimumab; dose must be no greater than 20mg (if weight \<30kg), or 40mg (if weight ≥30kg), injected every two weeks * If on biosimilar of adalimumab, ≥90 days on the biosimilar * Ability to continue to obtain commercial supply of adalimumab or biosimilar * If on a conventional disease-modifying anti-rheumatic drug (cDMARD) (injectable or oral methotrexate, mycophenolate mofetil, azathioprine, or leflunomide), dose must be ≤25 mg weekly for methotrexate, ≤3 g daily for mycophenolate mofetil, ≤250 mg daily for azathioprine, or ≤20 mg daily for leflunomide; dose and rout…